FKBP5 Gene Expression Predicts Antidepressant Treatment Outcome in Depression.
Adult
Alleles
Antidepressive Agents
/ therapeutic use
Biomarkers
Depression
/ diagnosis
Female
Gene Expression
Genotype
Humans
Hypothalamo-Hypophyseal System
/ drug effects
Longitudinal Studies
Male
Middle Aged
Pituitary-Adrenal System
/ drug effects
Prognosis
Tacrolimus Binding Proteins
/ genetics
Time Factors
Treatment Outcome
FKBP5
FKBP51
HPA axis
antidepressant treatment
depression
gene expression
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 Jan 2019
23 Jan 2019
Historique:
received:
09
12
2018
revised:
13
01
2019
accepted:
20
01
2019
entrez:
26
1
2019
pubmed:
27
1
2019
medline:
10
5
2019
Statut:
epublish
Résumé
Adverse experiences and chronic stress are well-known risk factors for the development of major depression, and an impaired stress response regulation is frequently observed in acute depression. Impaired glucocorticoid receptor (GR) signalling plays an important role in these alterations, and a restoration of GR signalling appears to be a prerequisite of successful antidepressant treatment. Variants in genes of the stress response regulation contribute to the vulnerability to depression in traumatized subjects. Consistent findings point to an important role of FKBP5, the gene expressing FK506-binding protein 51 (FKBP51), which is a strong inhibitor of the GR, and thus, an important regulator of the stress response. We investigated the role of FKBP5 and FKB51 expression with respect to stress response regulation and antidepressant treatment outcome in depressed patients. This study included 297 inpatients, who participated in the Munich Antidepressant Response Signature (MARS) project and were treated for acute depression. In this open-label study, patients received antidepressant treatment according to the attending doctor's choice. In addition to the
Identifiants
pubmed: 30678080
pii: ijms20030485
doi: 10.3390/ijms20030485
pmc: PMC6387218
pii:
doi:
Substances chimiques
Antidepressive Agents
0
Biomarkers
0
Tacrolimus Binding Proteins
EC 5.2.1.-
tacrolimus binding protein 5
EC 5.2.1.8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Bundesministerium für Bildung und Forschung
ID : 01ES0811
Déclaration de conflit d'intérêts
The authors F.H. and M.U are coinventors of the patent “FKBP51: a novel target for antidepressant therapy” (WO2005054500). All other authors declare no conflict of interest.
Références
Am J Psychiatry. 1999 Jun;156(6):837-41
pubmed: 10360120
Neuropsychopharmacology. 2000 Nov;23(5):477-501
pubmed: 11027914
Endocrinology. 2000 Nov;141(11):4107-13
pubmed: 11089542
J Psychiatr Res. 2001 Mar-Apr;35(2):83-94
pubmed: 11377437
Proteomics. 2002 Apr;2(4):383-93
pubmed: 12164697
J Clin Endocrinol Metab. 2003 Jan;88(1):277-84
pubmed: 12519866
Arch Gen Psychiatry. 2003 Sep;60(9):929-37
pubmed: 12963675
Nat Genet. 2004 Dec;36(12):1319-25
pubmed: 15565110
Nat Rev Neurosci. 2005 Jun;6(6):463-75
pubmed: 15891777
Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jul;29(6):1085-93
pubmed: 15950349
Biol Psychiatry. 2006 Apr 15;59(8):696-701
pubmed: 16368077
Handb Exp Pharmacol. 2006;(172):111-38
pubmed: 16610357
Biol Psychiatry. 2007 Jul 1;62(1):47-54
pubmed: 17123470
Clin Psychol Rev. 2007 Dec;27(8):959-85
pubmed: 17448579
Annu Rev Clin Psychol. 2005;1:293-319
pubmed: 17716090
JAMA. 2008 Mar 19;299(11):1291-305
pubmed: 18349090
Nat Protoc. 2008;3(6):1101-8
pubmed: 18546601
Nat Rev Genet. 2008 Jul;9(7):527-40
pubmed: 18560438
J Psychiatr Res. 2009 Jan;43(3):215-29
pubmed: 18586274
Psychoneuroendocrinology. 2008 Jul;33(6):693-710
pubmed: 18602762
Psychoneuroendocrinology. 2009 Dec;34 Suppl 1:S186-95
pubmed: 19560279
Am J Psychiatry. 2011 Oct;168(10):1107-16
pubmed: 21865530
J Neurochem. 2012 Jul;122(1):4-18
pubmed: 22548329
Neuropsychopharmacology. 2013 Feb;38(3):377-85
pubmed: 22990943
Nat Neurosci. 2013 Jan;16(1):33-41
pubmed: 23201972
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Aug 1;45:183-94
pubmed: 23733030
Psychoneuroendocrinology. 2014 Jun;44:112-22
pubmed: 24767625
PLoS Med. 2014 Nov 11;11(11):e1001755
pubmed: 25386878
Mol Psychiatry. 2016 Feb;21(2):277-89
pubmed: 25849320
J Neurosci. 2015 Jun 17;35(24):9007-16
pubmed: 26085626
Sci Signal. 2015 Nov 24;8(404):ra119
pubmed: 26602018
Bioessays. 2016 Sep;38(9):894-902
pubmed: 27374865
World J Biol Psychiatry. 2017 Feb;18(1):5-28
pubmed: 27603714
J Affect Disord. 2018 Jan 1;225:422-428
pubmed: 28850857
Philos Trans R Soc Lond B Biol Sci. 2018 Jan 19;373(1738):
pubmed: 29203717
Psychiatr Pol. 2017 Dec 30;51(6):1029-1038
pubmed: 29432501
ACS Chem Biol. 2018 Aug 17;13(8):2288-2299
pubmed: 29893552
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Br J Psychiatry. 1982 Jul;141:45-9
pubmed: 7116071
Arch Gen Psychiatry. 1981 Jan;38(1):98-103
pubmed: 7458574
J Psychiatr Res. 1994 Jul-Aug;28(4):341-56
pubmed: 7877114